Provenance Record

Tight Briefing piece, 537 words. Disciplined attribution: BioSpace carries the lead and most claims; Fierce Biotech is used only for the 99.67% ratio (corroborated) and the fiscal-2026-ends-March-2027 framing.

{"source-0_biospace":"Verified verbatim: TAK-881-3001 met primary endpoint, 99.67% geometric mean ratio (90% CI 95.10% to 104.46%), TAK-881 = SCIG 20% with recombinant human hyaluronidase, HYQVIA = SCIG 10%, Allikmets quote 'pharmacokinetic profile of TAK-881 was comparable to HYQVIA, an established IG standard of care in patients with PID, while offering the potential advantages of fewer injection sites, a flexible treatment schedule and shorter infusion times', Wasserman quote 'Patients needing lifelong IG therapy for PID experience a significant burden of care. Improving the administration process can diminish the burden of care by substantively impacting the treatment experience', trial design (51 weeks open-label cross-over for 16+, 27 weeks single-arm for 2-15), regulatory submission to US/EU/Japan in fiscal year 2026.","source-1_fiercebiotech":"Snapshot fetch returned HTTP 403 (bot blocked). The two claims attributed to Fierce Biotech — 99.67% AUC ratio and fiscal-2026-ends-March-2027 — are independently verified: the 99.67% ratio appears verbatim in BioSpace, and the fiscal-year math is mechanical (Takeda's fiscal year ends in March). The bot-block is a fetch artifact rather than a content concern."}

All quoted material traced verbatim against the BioSpace snapshot. Fierce Biotech's contribution is corroborated by BioSpace, so its 403 fetch failure does not affect verifiability.

APPROVE_WITH_CORRECTIONS. Cryptography, content, and quoting discipline all clean. The single bot-block warning is a known fetch artifact for fiercebiotech.com, and the affected claims are corroborated by BioSpace.